SecBot SecBot
SECBOTREPLAY Home › Report › ZLAB

ZLAB · Zai Lab reported strong financial results for Q4 and full-year 2025,…

Zai Lab Ltd · 8-K filed Feb 25, 2026 at 19:00 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 25, 2026 at 19:00 ET

Zai Lab reported strong financial results for Q4 and full-year 2025, with total revenue growing 17% YoY to $127.6 million in Q4 and 15% YoY to $460.2 million for the full year. The company achieved a 41% reduction in net loss to $175.5 million, driven by revenue growth outpacing expenses and improved foreign exchange performance. Key developments include the approval and upcoming commercial launch of KarXT in China, advancement of its global oncology pipeline including zoci, and positive clinical data for VYVGART in ocular myasthenia gravis.

  • Total revenue grew 17% YoY to $127.6 million in Q4 2025 and 15% YoY to $460.2 million for full-year 2025
  • Net loss decreased 32% YoY to $175.5 million for full-year 2025, with Q4 net loss down 38% to $50.4 million
  • KarXT approved in China for schizophrenia treatment and commercial launch planned for H1 2026
  • VYVGART Phase 3 trial met primary endpoint for ocular myasthenia gravis with statistically significant improvement

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access